167 related articles for article (PubMed ID: 21695734)
21. The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.
Kuzman MR; Medved V; Bozina N; Hotujac L; Sain I; Bilusic H
Psychiatry Res; 2008 Sep; 160(3):308-15. PubMed ID: 18718676
[TBL] [Abstract][Full Text] [Related]
22. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
Poyurovsky M; Pashinian A; Gil-Ad I; Maayan R; Schneidman M; Fuchs C; Weizman A
Am J Psychiatry; 2002 Jun; 159(6):1058-60. PubMed ID: 12042201
[TBL] [Abstract][Full Text] [Related]
23. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
Bhowmick S; Hazra A; Ghosh M
Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717
[TBL] [Abstract][Full Text] [Related]
24. Associations among obesity, acute weight gain, and response to treatment with olanzapine in adolescent schizophrenia.
Kemp DE; Correll CU; Tohen M; Delbello MP; Ganocy SJ; Findling RL; Chang K
J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):522-30. PubMed ID: 24111982
[TBL] [Abstract][Full Text] [Related]
25. Association between ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients.
Yang Y; Li W; Zhao J; Zhang H; Song X; Xiao B; Yang G; Jiang C; Zhang D; Yue W; Lv L
Behav Brain Funct; 2012 Feb; 8():11. PubMed ID: 22369141
[TBL] [Abstract][Full Text] [Related]
26. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
Citrome L; Holt RI; Walker DJ; Hoffmann VP
Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
[TBL] [Abstract][Full Text] [Related]
27. Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination.
Poyurovsky M; Fuchs C; Pashinian A; Levi A; Weizman R; Weizman A
Psychopharmacology (Berl); 2013 Apr; 226(3):615-22. PubMed ID: 23239133
[TBL] [Abstract][Full Text] [Related]
28. Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine.
Chagnon YC; Bureau A; Gendron D; Bouchard RH; Mérette C; Roy MA; Maziade M
Am J Med Genet B Neuropsychiatr Genet; 2007 Dec; 144B(8):1063-9. PubMed ID: 17541984
[TBL] [Abstract][Full Text] [Related]
29. Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene.
Godlewska BR; Olajossy-Hilkesberger L; Ciwoniuk M; Olajossy M; Marmurowska-Michałowska H; Limon J; Landowski J
Pharmacogenomics J; 2009 Aug; 9(4):234-41. PubMed ID: 19434072
[TBL] [Abstract][Full Text] [Related]
30. Genetic association analysis of CNR1 and CNR2 polymorphisms with schizophrenia in a Korean population.
Bae JS; Kim JY; Park BL; Kim JH; Kim B; Park CS; Kim BJ; Lee CS; Lee M; Choi WH; Shin TM; Hwang J; Shin HD; Woo SI
Psychiatr Genet; 2014 Oct; 24(5):225-9. PubMed ID: 25014618
[TBL] [Abstract][Full Text] [Related]
31. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study.
Poyurovsky M; Fuchs C; Pashinian A; Levi A; Faragian S; Maayan R; Gil-Ad I
Psychopharmacology (Berl); 2007 Jun; 192(3):441-8. PubMed ID: 17310385
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms of the histamine receptor (H1HR) gene are not associated with olanzapine-induced weight gain.
Godlewska BR; Olajossy-Hilkesberger L; Olajossy M; Limon J; Landowski J
J Clin Psychopharmacol; 2013 Jun; 33(3):436-7. PubMed ID: 23609395
[No Abstract] [Full Text] [Related]
33. Association of CNR1 and INSIG2 polymorphisms with antipsychotics-induced weight gain: a prospective nested case-control study.
Jimeno N; Velasco-Gonzalez V; Fierro I; Duran M; Carvajal A
Sci Rep; 2021 Jul; 11(1):15304. PubMed ID: 34315947
[TBL] [Abstract][Full Text] [Related]
34. Alterations to melanocortinergic, GABAergic and cannabinoid neurotransmission associated with olanzapine-induced weight gain.
Weston-Green K; Huang XF; Deng C
PLoS One; 2012; 7(3):e33548. PubMed ID: 22438946
[TBL] [Abstract][Full Text] [Related]
35. Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats.
Lazzari P; Serra V; Marcello S; Pira M; Mastinu A
Eur Neuropsychopharmacol; 2017 Jul; 27(7):667-678. PubMed ID: 28377074
[TBL] [Abstract][Full Text] [Related]
36. Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database.
Bushe CJ; Slooff CJ; Haddad PM; Karagianis JL
J Psychopharmacol; 2013 Apr; 27(4):358-65. PubMed ID: 23343595
[TBL] [Abstract][Full Text] [Related]
37. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
38. TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Huang HH; Wang YC; Wu CL; Hong CJ; Bai YM; Tsai SJ; Liou YJ
Neurosci Lett; 2011 Oct; 504(3):277-80. PubMed ID: 21967963
[TBL] [Abstract][Full Text] [Related]
39. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.
Milano W; Grillo F; Del Mastro A; De Rosa M; Sanseverino B; Petrella C; Capasso A
Adv Ther; 2007; 24(1):123-34. PubMed ID: 17526469
[TBL] [Abstract][Full Text] [Related]
40. Olanzapine increases plasma ghrelin level in patients with schizophrenia.
Murashita M; Kusumi I; Inoue T; Takahashi Y; Hosoda H; Kangawa K; Koyama T
Psychoneuroendocrinology; 2005 Jan; 30(1):106-10. PubMed ID: 15358448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
